# Phase 2 hematologic cancer trials recruiting: 45 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 45 trials in phase 2 for hematologic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 hematologic cancer trials: 45 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/hematologic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 45
- Recruiting or not yet: 45
- Read on: November 19, 2026

## Trials

The 25 newest of 45, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926698 | Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Multicenter Single-Arm... | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Hematologic Malignancies, Haploidentical Peripheral Blood Stem Cell Transplantation, Acute Graft-Versus-Host Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926698) |
| November 9, 2026 | NCT07926217 | High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy | Sponsor not shown (see the record) | Phase 2 | Recruiting | Hematologic Malignancy, Influenza | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926217) |
| October 23, 2026 | NCT07891533 | Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera | AN2 Therapeutics, Inc | Phase 2 | Not yet recruiting | Polycythemia Vera (SNOMED CT: 109992005) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891533) |
| September 8, 2026 | NCT07808112 | CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell... | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Graft -Versus-host-disease | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808112) |
| July 22, 2026 | NCT07719946 | To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers | Tata Memorial Centre | Phase 2 | Recruiting | Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719946) |
| July 16, 2026 | NCT07709195 | Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant | Tata Memorial Centre | Phase 2 | Recruiting | Oral Mucositis, Total Body Irradiation, Hematological Malignancies, Hematopoietic Stem Cell Transplantation (HSCT) | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709195) |
| July 16, 2026 | NCT07709013 | Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients | Tata Memorial Centre | Phase 2 | Recruiting | Hematologic Malignancies | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709013) |
| July 16, 2026 | NCT07709000 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709000) |
| July 16, 2026 | NCT07708987 | Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease. | Tata Memorial Centre | Phase 2 | Recruiting | Hematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod Refractory | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708987) |
| April 13, 2026 | NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524530) |
| March 2, 2026 | NCT07441967 | The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single... | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Hematologic Malignancies | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441967) |
| January 22, 2026 | NCT07359859 | A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell... | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Hematologic Malignancies | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359859) |
| October 14, 2025 | NCT07216443 | Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic... | Orca Biosystems, Inc. | Phase 2 | Recruiting | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216443) |
| August 22, 2025 | NCT07137481 | Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the... | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Hematological Malignancies | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07137481) |
| June 29, 2025 | NCT07043894 | Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Solid Tumors, Hematological Tumor, Children, Adolescent, Chemotherapy Induced Thrombocytopenia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07043894) |
| June 5, 2025 | NCT07006506 | A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07006506) |
| April 13, 2025 | NCT06926595 | Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention | Milton S. Hershey Medical Center | Phase 2 | Recruiting | Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926595) |
| February 4, 2025 | NCT06807606 | Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Hematologic Malignancies | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06807606) |
| January 29, 2025 | NCT06799195 | Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation | University of Nebraska | Phase 2 | Recruiting | Hematological Malignancies, Graft-versus-Host Disease (GVHD) | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06799195) |
| January 17, 2025 | NCT06782373 | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | Swedish Orphan Biovitrum | Phase 2 | Recruiting | VEXAS, VEXAS Syndrome | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06782373) |
| October 30, 2024 | NCT06665100 | PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) | Pulmotect, Inc. | Phase 2 | Recruiting | Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06665100) |
| September 4, 2024 | NCT06584006 | Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors | The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | Hematological Malignancy, Lymphocytopenia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06584006) |
| August 7, 2024 | NCT06541067 | Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal... | Nantes University Hospital | Phase 2 | Recruiting | Hematologic Malignancy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06541067) |
| July 19, 2024 | NCT06510699 | Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial | The University of Queensland | Phase 2 | Recruiting | Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06510699) |
| July 1, 2024 | NCT06482515 | Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue | University of Maryland, Baltimore | Phase 2 | Recruiting | Neoplasms, Blood Cancer, Fatigue, Diet Habit, Survivorship, Fasting, Intermittent | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06482515) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 5 |
| Tata Memorial Centre | 4 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Nantes University Hospital | 2 |
| Anhui Provincial Hospital | 1 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| Medical College of Wisconsin | 1 |
| Cogent Biosciences, Inc. | 1 |
| West Virginia University | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Henry Ford Health System | 1 |
| Ottawa Hospital Research Institute | 1 |
| Pulmotect, Inc. | 1 |
| University of California, Irvine | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 1 |
| The University of Queensland | 1 |
| University of Florida | 1 |
| University of Maryland, Baltimore | 1 |
| University Hospital, Clermont-Ferrand | 1 |
| Helsinki University Central Hospital | 1 |
| Milton S. Hershey Medical Center | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 25 |
| France | 8 |
| Spain | 7 |
| China | 5 |
| Italy | 5 |
| Germany | 5 |
| South Korea | 4 |
| Australia | 4 |
| Belgium | 4 |
| Canada | 4 |
| Poland | 4 |
| India | 4 |
| Hungary | 3 |
| Turkey (Türkiye) | 3 |
| Netherlands | 3 |
| United Kingdom | 3 |
| Israel | 3 |
| Austria | 2 |
| Switzerland | 2 |
| Czechia | 2 |
| Finland | 2 |
| Japan | 2 |
| Norway | 1 |
| Croatia | 1 |
| Portugal | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [African restaurants in the United States](https://specstream.ai/data/businesses/african-restaurants/united-states)
- [Vegetarian restaurants in the United States](https://specstream.ai/data/businesses/vegetarian-restaurants/united-states)
- [Taco restaurants in the United States](https://specstream.ai/data/businesses/taco-restaurants/united-states)
- [Security companies in the United States](https://specstream.ai/data/businesses/security-companies/united-states)
- [Prosthetics providers in the United States](https://specstream.ai/data/businesses/prosthetics-providers/united-states)
- [Pediatric dentistry practices in the United States](https://specstream.ai/data/businesses/pediatric-dentistry-practices/united-states)
